Medtronic PLC’sbombshell news – the disappointing clinical results for its Simplicity renal denervation product – left a smoking crater on the medtech landscape during last week’s J.P. Morgan Healthcare Conference in San Francisco. Large-cap executives and venture capitalists who saw great promise in the new therapeutic approach spent time trying to gauge the size and scope of the damage on the medtech industry and their own particular portfolios.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?